Florida Medicaid and tirzepatide
Florida Medicaid did not cover GLP-1s for weight loss as of January 2026, according to KFF, though it must cover them for type 2 diabetes.
In 2025 Florida Medicaid paid for 15,477 tirzepatide prescriptions (Mounjaro, Zepbound), 12% of its GLP-1 prescriptions and 29th of the 50 states and DC. It reimbursed $15.7 million before rebates, $1,017 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 15,286 | $15.5 million | $1,016 |
| Zepbound | 191 | $197,852 | $1,036 |
Florida plans and prescribing rules
State of Florida employee health plan (Division of State Group Insurance). Florida's state employee plan offers FDA-approved weight management medications only through its Weight Management Program, which is limited to 2,800 members who meet its eligibility criteria.
Florida Blue. Florida Blue's January 2025 provider notice says medications used for weight loss or weight management are excluded from its health insurance plans, so authorization requests for Wegovy, Zepbound or Saxenda for weight loss are denied.



